Journal of Thrombosis and Thrombolysis

, Volume 38, Issue 1, pp 81–86

Preprocedural TIMI flow and infarct size in STEMI undergoing primary angioplasty

  • Giuseppe De Luca
  • Guido Parodi
  • Roberto Sciagrà
  • Francesco Venditti
  • Benedetta Bellandi
  • Ruben Vergara
  • Angela Migliorini
  • Renato Valenti
  • David Antoniucci
Article

Abstract

Despite optimal epicardial recanalization, primary angioplasty for STEMI is still associated with suboptimal reperfusion in a relatively large proportion of patients. The aim the current study was to evaluate the impact of preprocedural TIMI flow on myocardial scintigraphic infarct size among STEMI undergoing primary angioplasty. Our population is represented by 793 STEMI patients undergoing primary PCI. Infarct size was evaluated at 30 days by technetium-99m-sestamibi. Poor preprocedural TIMI flow (TIMI 0–1) was observed in 645 patients (81.3 %). Poor preprocedural TIMI flow was associated with more hypercholesterolemia (p = 0.012), and a trend in lower prevalence of diabetes (p = 0.081). Preprocedural TIMI flow significantly affected scintigraphic and enzymatic infarct size. Similar findings were observed in the analysis restricted to patients with postprocedural TIMI 3 flow. The impact of preprocedural TIMI flow on scintigraphic infarct size was confirmed when the analysis was performed according to the percentage of patients above the median (p < 0.001) and after adjustment for baseline confounding factors (Hypercholesterolemia and diabetes) [adjusted OR (95 % CI) for pre preprocedural TIMI 3 flow = 0.59 (0.46–0.75), p < 0.001]. This study shows that among patients with STEMI undergoing primary angioplasty, poor preprocedural TIMI flow is independently associated with larger infarct size.

Keywords

STEMI Primary angioplasty Preprocedural recanalization Infarct size SPECT 

References

  1. 1.
    De Luca G, Cassetti E, Marino P (2009) Percutaneous coronary intervention-related time delay, patient’s risk profile, and survival benefits of primary angioplasty vs lytic therapy in ST-segment elevation myocardial infarction. Am J Emerg Med 27:712–719PubMedCrossRefGoogle Scholar
  2. 2.
    De Luca G, Biondi-Zoccai G, Marino P (2008) Transferring patients with ST-segment elevation myocardial infarction for mechanical reperfusion: a meta-regression analysis of randomized trials. Ann Emerg Med 52:665–676PubMedCrossRefGoogle Scholar
  3. 3.
    De Luca G, Cassetti E, Verdoia M, Marino P (2009) Bivalirudin as compared to unfractionated heparin among patients undergoing coronary angioplasty: a meta-analyis of randomised trials. Thromb Haemost 102:428–436PubMedGoogle Scholar
  4. 4.
    De Luca G, Suryapranata H, Stone GW, Antoniucci D, Tcheng JE, Neumann FJ, Van de Werf F, Antman EM, Topol EJ (2005) Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 293:1759–1765PubMedCrossRefGoogle Scholar
  5. 5.
    Di Lorenzo E, Sauro R, Varricchio A, Capasso M, Lanzillo T, Manganelli F, Mariello C, Siano F, Pagliuca MR, Stanco G, Rosato G, De Luca G (2009) Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial. Am Heart J 158:e43–e50PubMedCrossRefGoogle Scholar
  6. 6.
    De Luca G, Navarese EP, Suryapranata H (2012) A meta-analytic overview of thrombectomy during primary angioplasty. Int J Cardiol. doi:10.1016/j.ijcard.2011.11.102 Google Scholar
  7. 7.
    Sakuma T, Leong-Poi H, Fisher NG et al (2003) Further insights into the no-reflow phenomenon after primary angioplasty in acute myocardial infarction: the role of microthromboemboli. J Am Soc Echocardiogr 16:15–21PubMedCrossRefGoogle Scholar
  8. 8.
    De Luca G, van’t Hof AW, Ottervanger JP, Hoorntje JC, Gosselink AT, Dambrink JH, Zijlstra F, de Boer MJ, Suryapranata H (2005) Unsuccessful reperfusion in patients with ST-segment elevation myocardial infarction treated by primary angioplasty. Am Heart J 150:557–562PubMedCrossRefGoogle Scholar
  9. 9.
    Brodie BR, Stuckey TD, Wall TC, Kissling G, Hansen CJ, Muncy DB, Weintraub RA, Kelly TA (1998) Importance of time to reperfusion for 30-day and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 32:1312–1319PubMedCrossRefGoogle Scholar
  10. 10.
    Antoniucci D, Valenti R, Migliorini A, Moschi G, Trapani M, Buonamici P, Cerisano G, Bolognese L, Santoro GM (2002) Relation of time to treatment and mortality in patients with acute myocardial infarction undergoing primary coronary angioplasty. Am J Cardiol 89:1248–1252PubMedCrossRefGoogle Scholar
  11. 11.
    De Luca G, van’t Hof AW, de Boer MJ, Ottervanger JP, Hoorntje JC, Gosselink AT, Dambrink JH, Zijlstra F, Suryapranata H (2004) Time-to-treatment significantly affects the extent of ST-segment resolution and myocardial blush in patients with acute myocardial infarction treated by primary angioplasty. Eur Heart J 25:1009–1013PubMedCrossRefGoogle Scholar
  12. 12.
    De Luca G, Suryapranata H, Ottervanger JP, Antman EM (2004) Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation 109:1223–1225PubMedCrossRefGoogle Scholar
  13. 13.
    Rathore SS, Curtis JP, Chen J, Wang Y, Nallamothu BK, Epstein AJ, Krumholz HM, National Cardiovascular Data Registry (2009) Association of door-to-balloon time and mortality in patients admitted to hospital with ST elevation myocardial infarction: national cohort study. BMJ 338:b1807. doi:10.1136/bmj.b1807 PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Zahn R, Vogt A, Zeymer U, Gitt AK, Seidl K, Gottwik M, Weber MA, Niederer W, Mödl B, Engel HJ, Tebbe U, Senges J, Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (2005) In-hospital time to treatment of patients with acute ST elevation myocardial infarction treated with primary angioplasty: determinants and outcome. Results from the registry of percutaneous coronary interventions in acute myocardial infarction of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte. Heart 91:1041–1046PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Stone GW, Cox D, Garcia E, Brodie BR, Morice MC, Griffin J, Mattos L, Lansky AJ, O’Neill WW, Grines CL (2001) Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials. Circulation 104:636–641PubMedCrossRefGoogle Scholar
  16. 16.
    Brodie BR, Stuckey TD, Hansen C, Muncy D (2000) Benefit of coronary reperfusion before intervention on outcomes after primary angioplasty for acute myocardial infarction. Am J Cardiol 85:13–18PubMedCrossRefGoogle Scholar
  17. 17.
    De Luca G, Ernst N, Zijlstra F, van ‘t Hof AW, Hoorntje JC, Dambrink JH, Gosslink AT, de Boer MJ, Suryapranata H (2004) Preprocedural TIMI flow and mortality in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll Cardiol 43:1363–1367PubMedCrossRefGoogle Scholar
  18. 18.
    De Luca G, Ernst N, van’t Hof AW, Ottervanger JP, Hoorntje JC, Dambrink JH, Gosselink AT, de Boer MJ, Suryapranata H (2005) Preprocedural Thrombolysis in Myocardial Infarction (TIMI) flow significantly affects the extent of ST-segment resolution and myocardial blush in patients with acute anterior myocardial infarction treated by primary angioplasty. Am Heart J 150:827–831PubMedCrossRefGoogle Scholar
  19. 19.
    Dudek D, Rakowski T, El Massri N, Sorysz D, Zalewski J, Legutko J, Dziewierz A, Rzeszutko L, Zmudka K, Piwowarska W, De Luca G, Kaluza GL, Janion M, Dubiel JS (2008) Patency of infarct related artery after pharmacological reperfusion during transfer to primary percutaneous coronary intervention influences left ventricular function and one-year clinical outcome. Int J Cardiol 124:326–331PubMedCrossRefGoogle Scholar
  20. 20.
    Maioli M, Zeymer U, van’t Hof AW, Gibson CM, Dudek D, Bellandi F, Noc M, Secco GG, Zorman S, Gabriel HM, Emre A, Cutlip D, Rakowski T, Gyongyosi M, Huber K, De Luca G, EGYPT Cooperation (2012) Impact of preprocedural TIMI flow on myocardial perfusion, distal embolization and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb/IIIa inhibitors. J Invasive Cardiol 24:324–327PubMedGoogle Scholar
  21. 21.
    Ndrepepa G, Kastrati A, Schwaiger M, Mehilli J, Markwardt C, Dibra A, Dirschinger J, Schömig A (2005) Relationship between residual blood flow in the infarct-related artery and scintigraphic infarct size, myocardial salvage, and functional recovery in patients with acute myocardial infarction. J Nucl Med 46:1782–1788PubMedGoogle Scholar
  22. 22.
    Sciagrà R, Imperiale A, Antoniucci D, Migliorini A, Parodi G, Comis G, Pupi A (2004) Relationship of infarct size and severity versus left ventricular ejection fraction and volumes obtained from 99mTc-sestamibi gated single-photon emission computed tomography in patients treated with primary percutaneous coronary intervention. Eur J Nucl Med Mol Imaging 31:969–974PubMedCrossRefGoogle Scholar
  23. 23.
    O’Connor MK, Hammel T, Gibbons RJ (1990) In vitro validation of a simple tomographic technique for estimation of percentage myocardium at risk using methoxyisobutyl isonitrile technetium 99m (sestamibi). Eur J Nucl Med 17:69–76PubMedCrossRefGoogle Scholar
  24. 24.
    De Luca G, Ernst N, Suryapranata H, Ottervanger JP, Hoorntje JC, Gosselink AT, Dambrink JH, de Boer MJ, van’t Hof AW (2005) Relation of interhospital delay and mortality in patients with ST-segment elevation myocardial infarction transferred for primary coronary angioplasty. Am J Cardiol 95:1361–1363PubMedCrossRefGoogle Scholar
  25. 25.
    Reimer KA, Vander Heide RS, Richard VJ (1993) Reperfusion in acute myocardial infarction: effects of timing and modulating factors in experimental models. Am J Cardiol 72:13G–21GPubMedCrossRefGoogle Scholar
  26. 26.
    Garcia-Dorado D, Theroux P, Elizaga J, Galinanes S, Solares J, Riesgo M, Gomez MJ, Garcia-Dorado A, Fernandez Aviles F (1987) Myocardial infarction in the pig heart model: infarct size and duration of coronary occlusion. Cardiovasc Res 21:537–544PubMedCrossRefGoogle Scholar
  27. 27.
    Silvain J, Collet JP, Nagaswami C, Beygui F, Edmondson KE, Bellemain-Appaix A, Cayla G, Pena A, Brugier D, Barthelemy O, Montalescot G, Weisel JW (2011) Composition of coronary thrombus in acute myocardial infarction. J Am Coll Cardiol 57:1359–1367PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    De Luca G, Gibson CM, Bellandi F, Noc M, Maioli M, Zorman S, Zeymer U, Gabriel HM, Emre A, Cutlip D, Arntz HR, Dudek D, Rakowski T, Gyongyosi M, Huber K, van’t Hof AW (2010) Impact of distal embolization on myocardial perfusion and survival among patients undergoing primary angioplasty with glycoprotein IIb-IIIa inhibitors: insights from the EGYPT cooperation. J Thromb Thrombolysis 30(1):23–28PubMedCrossRefGoogle Scholar
  29. 29.
    Herrmann HC, Lu J, Brodie BR, Armstrong PW, Montalescot G, Betriu A, Neuman FJ, Effron MB, Barnathan ES, Topol EJ, Ellis SG, FINESSE Investigators (2009) Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to non percutaneous coronary intervention hospitals. JACC Cardiovasc Interv 2:917–924PubMedCrossRefGoogle Scholar
  30. 30.
    De Luca G, Gibson CM, Bellandi F, Murphy S, Maioli M, Noc M, Zeymer U, Dudek D, Arntz HR, Zorman S, Gabriel HM, Emre A, Cutlip D, Biondi-Zoccai G, Rakowski T, Gyongyosi M, Marino P, Huber K, van’t Hof AW (2008) Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis. Heart 94:1548–1558PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    De Luca G, Bellandi F, Huber K, Noc M, Petronio AS, Arntz HR, Maioli M, Gabriel HM, Zorman S, Carlo M DE, Rakowski T, Gyongyosi M, Dudek D (2011) Early glycoprotein IIb-IIIa inhibitors in primary angioplasty-abciximab long-term results (EGYPT-ALT) cooperation: individual patient’s data meta-analysis. J Thromb Haemost 9:2361–2370CrossRefGoogle Scholar
  32. 32.
    Dudek D, Siudak Z, Janzon M, Birkemeyer R, Aldama-Lopez G, Lettieri C, Janus B, Wisniewski A, Berti S, Olivari Z, Rakowski T, Partyka L, Goedicke J, Zmudka K, EUROTRANSFER Registry Investigators (2008) European registry on patients with ST-elevation myocardial infarction transferred for mechanical reperfusion with a special focus on early administration of abciximab—EUROTRANSFER Registry. Am Heart J 156:1147–1154PubMedCrossRefGoogle Scholar
  33. 33.
    Ortolani P, Marzocchi A, Marrozzini C, Palmerini T, Saia F, Taglieri N, Baldazzi F, Dall’Ara G, Nardini P, Gianstefani S, Guastaroba P, Grilli R, Branzi A (2009) Long-term effectiveness of early administration of glycoprotein IIb/IIIa agents to real-world patients undergoing primary percutaneous interventions: results of a registry study in an ST-elevation myocardial infarction network. Eur Heart J 30:33–43PubMedCrossRefGoogle Scholar
  34. 34.
    Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van’t Hof A, Widimsky P, Zahger D (2012) ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 33(20):2569–2619PubMedCrossRefGoogle Scholar
  35. 35.
    Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y, Sulimov V, Rosell Ortiz F, Ostojic M, Welsh RC, Carvalho AC, Nanas J, Arntz HR, Halvorsen S, Huber K, Grajek S, Fresco C, Bluhmki E, Regelin A, Vandenberghe K, Bogaerts K, Van de Werf F, STREAM Investigative Team (2013) Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med 368:1379–1387PubMedCrossRefGoogle Scholar
  36. 36.
    Sinusas AJ, Shi Q, Vitols PJ, Fetterman RC, Maniawski P, Zaret BL, Wackers FJ (1993) Impact of regional ventricular function, geometry, and dobutamine stress on quantitative 99mTc-sestamibi defect size. Circulation 88:2224–2234PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Giuseppe De Luca
    • 1
  • Guido Parodi
    • 2
  • Roberto Sciagrà
    • 3
  • Francesco Venditti
    • 2
  • Benedetta Bellandi
    • 2
  • Ruben Vergara
    • 2
  • Angela Migliorini
    • 2
  • Renato Valenti
    • 2
  • David Antoniucci
    • 2
  1. 1.Division of Cardiology“Maggiore della Carità” Hospital, Eastern Piedmont UniversityNovaraItaly
  2. 2.Division of CardiologyCareggi HospitalFlorenceItaly
  3. 3.Nuclear Medicine UnityUniversity of FlorenceFlorenceItaly

Personalised recommendations